Ajanta Pharma reported a 56% increase in consolidated net profit of Rs 210 crore for the Oct-Dec quarter. Revenue also rose by 14% to Rs 1,105 crore and EBITDA increased by 85%. The company's Board approved a second interim dividend of Rs 26 per share. India branded generics contributed Rs 308 crore while US generics brought in Rs 252 crore of its total revenue.